Holen Sie sich die Stockscreener-App
13.99
4.33%
0.58
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics Elects New Directors at Annual Meeting - TipRanks
US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs - marketscreener.com
Dyne Therapeutics (DYN) Unveils Promising Preclinical Data on DY - GuruFocus
Dyne Therapeutics to Present New Preclinical Data in Facioscapul - GuruFocus
Dyne Therapeutics Announces Functional Improvement of DYNE-302 in FSHD Preclinical Model - Nasdaq
Dyne Therapeutics to Present New Preclinical Data in - GlobeNewswire
Breakthrough: New FSHD Treatment Restores Muscle Function in Single Dose, Dyne Reports - Stock Titan
Dyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Up 56.1% in May - Defense World
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Oppenheimer - Defense World
Dyne Therapeutics (DYN) Target Price Adjusted by Oppenheimer | D - GuruFocus
Oppenheimer Adjusts Dyne Therapeutics Price Target to $34 From $60, Maintains Outperform Rating - marketscreener.com
Oppenheimer Sees Potential in Dyne Therapeutics (DYN) with Revised Price Target | DYN Stock News - GuruFocus
(DYN) Technical Data - news.stocktradersdaily.com
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 5.5% – Here’s What Happened - Defense World
Bank of America Corp DE Decreases Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Evercore ISI - Defense World
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Brokerages - Defense World
Dyne Therapeutics (DYN) Receives Outperform Rating as Confidence Grows | DYN Stock News - GuruFocus
Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com
Ameriprise Financial Inc. Increases Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Deutsche Bank AG Has $1.67 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics Inc (DYN) Volatility Hits 6.09%: What Good Investors Need To Be Aware Of - Stocksregister
How to Take Advantage of moves in (DYN) - news.stocktradersdaily.com
66,998 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by BNP Paribas Financial Markets - Defense World
Antibody Conjugate Oligonucleotide Market Research 2025-2035, Competitive Analysis of Key PlayersAvidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, and AstraZenecaResearchAndMarkets.com - Bluefield Daily Telegraph
Dimensional Fund Advisors LP Sells 66,569 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Northern Trust Corp Increases Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Pre-market Movers: CNSP, XLO, PLRZ, SGMO... - RTTNews
H.C. Wainwright cuts Dyne Therapeutics target to $38 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Dyne Therapeutics target to $38 - Investing.com
H.C. Wainwright Adjusts Price Target for Dyne Therapeutics (DYN) - GuruFocus
Dyne Therapeutics (DYN) Price Target Lowered by HC Wainwright & Co. | DYN Stock News - GuruFocus
Chardan Capital Reconfirms Buy Rating for Dyne Therapeutics (DYN - GuruFocus
RBC Cuts Price Target on Dyne Therapeutics to $30 From $36, Keeps Outperform, Speculative Risk - marketscreener.com
H.C. Wainwright Adjusts Price Target for Dyne Therapeutics (DYN) | DYN Stock News - GuruFocus
Chardan Capital Reconfirms Buy Rating for Dyne Therapeutics (DYN) | DYN Stock News - GuruFocus
Dyne Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your RightsDYN - ACCESS Newswire
Decoding Dyne Therapeutics Inc (DYN): A Strategic SWOT Insight - GuruFocus
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Dyne Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates - Nasdaq
Dyne (DYN) Eyes Accelerated Approval for Key Programs by 2026 | DYN Stock News - GuruFocus
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | DYN Stock News - GuruFocus
Dyne Therapeutics, Inc. SEC 10-Q Report - TradingView
Dyne Therapeutics, Inc. (NASDAQ:DYN) Stake Cut by Invesco Ltd. - Defense World
Wells Fargo & Company MN Raises Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Raymond James Financial Inc. Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Investors Who Lost Money on Dyne Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationDYN - ACCESS Newswire
Is Dyne Therapeutics Inc. (NASDAQ:DYN) the Most Promising Small-Cap Stock According to Analysts? - Insider Monkey
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy - Yahoo Finance
11 Most Promising Small-Cap Stocks According to Analysts - Insider Monkey
Dyne Therapeutics Gets EU Orphan Drug Status for Duchenne Treatment - marketscreener.com
Dyne Therapeutics stock rises on orphan drug status By Investing.com - Investing.com Canada
Dyne Therapeutics stock rises on orphan drug status - Investing.com
Dyne Therapeutics (DYN) Gains EU Orphan Drug Status for DYNE-251 - GuruFocus
0.86%
1.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):